NASDAQ: PROFProfound Medical Corp Stock
$6.71+0.08 (+1.21%)
Updated Jun 15, 2026
PROF Price
$6.71
Fair Value Price
N/A
Market Cap
$243.83M
52 Week Low
$3.76
52 Week High
$8.95
P/E
-7.36x
P/B
5.58x
P/S
17.25x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.83M
Earnings
-$28.19M
Gross Margin
71.1%
Operating Margin
-210.83%
Profit Margin
-206.8%
Debt to Equity
0.24
Operating Cash Flow
-$28M
Beta
1.06
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PROF Overview
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PROF's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
PROF
Ranked#65 of 94
Ranked#65 of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.60 | A | |
| $37.44 | A | |
| $26.36 | A |
Be the first to know about important PROF news, forecast changes, insider trades & much more!
PROF News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PROF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PROF is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PROF is poor value based on its book value relative to its share price (5.58x), compared to the US Medical Devices industry average (2.97x)
P/B vs Industry Valuation
PROF is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PROF due diligence checks available for Premium users.
Valuation
PROF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.36x
Industry
20.39x
Market
14.3x
PROF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.58x
Industry
2.97x
PROF is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PROF's financial health
Profit margin
Revenue
$3.9M
Net Income
-$5.1M
Profit Margin
-132.2%
PROF's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PROF's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.2M
Liabilities
$10.2M
Debt to equity
0.24
PROF's short-term assets ($51.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PROF's short-term assets ($51.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PROF's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PROF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
$0.0
Financing
$0.0
PROF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PROF vs Medical Device Stocks
Profound Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.